FDA deems Novartis AHF drug serelaxin 'breakthrough'
This article was originally published in Scrip
Executive Summary
Novartis won a second breakthrough therapy designation from the US FDA for another of the Swiss drug maker's experimental medicines, this time for its investigational acute heart failure (AHF) drug serelaxin (RLX030).